Inhibrx falls on wider-than-expected quarterly loss

Inhibrx Biosciences

14/08/2026 16:47

** Shares of drug developer Inhibrx Biosciences INBX.O fall 8.2% to $89.09 
** Co reports Q2 net loss of $36.7 million vs analysts' average estimate of a $29.6 million loss, according to LSEG data
** INBX's general and administrative expenses rise to $8.3 million during the quarter from $6.4 million a year ago
** Says the increase was primarily driven by pre-commercialization costs for the potential launch of its experimental drug, ozekibart
** The drug is being developed to treat conventional chondrosarcoma, a rare cancer that starts in bone cartilage
** Including session's move, stock up 12.8% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))